Well, moving on, it’s really been a tremendous afternoon. First, a huge shout-out to Charlie and our folks at VJHemOnc for bringing us together. I think this has been one of the most interesting discussions that I know I’ve been able to witness over this past year or two, so I really appreciate that, particularly Dr...
Well, moving on, it’s really been a tremendous afternoon. First, a huge shout-out to Charlie and our folks at VJHemOnc for bringing us together. I think this has been one of the most interesting discussions that I know I’ve been able to witness over this past year or two, so I really appreciate that, particularly Dr. Robluski and Moliterno for their expertise, as well as, again, this is not the normal venue, so I appreciate you guys being here and being willing to be involved in the conversation. So very much like the last talk, we’ve delved a little bit into my topic, so I’m going to try to focus on a few key things in terms of observations regarding symptoms and benefit, and just some observations about thoughts as they relate particularly to this issue of frontline and second-line therapy in myelofibrosis.
So here are my disclosures. One could say I’m heavily conflicted, or equally conflicted is the way I like to look at things.
So first, we set goals for an MPN therapy. I mentioned this earlier, but I think it is very true that truly there are only two things a therapy really can do, and it’s really not limited to cancer. I mean, whether you’re getting an antibiotic for strep throat, why do we treat that? Because again, in the worst-case scenario, it could be a fatal infection. So in the end, we can either live longer, we can live better, or both. As well, do not think that just living better is some sort of superficial, no-big-deal thing that anything can do. That is not true. You know, as someone who’s been involved with MPNs for a long time, kind of before the JAK inhibitor and after, we had lots of therapies that did not help people feel better at all. It was only when we really started having true efficacy against the biology of the disease that people actually started feeling better. I know because we did like 30 trials before that. They didn’t do squat. People did not feel better. We didn’t have PROs because we didn’t need them, because people felt terrible pre-therapy, and we did well if the therapy did not make them feel worse.
Now, what does living better with an MPN look like? And I really appreciate Werner coming, particularly all the way from Europe, for this perspective, because it’s really a key thing. So symptoms are a part of this, but it clearly isn’t limited to that. So one, decreasing fatigue. People can sometimes diminish fatigue, “well, let’s just swat that away,” but I want people to remember those comments, that every physician basically blew off this individual who said that fatigue was her major thing, and every physician had the circular firing squad of saying that it’s somebody else’s responsibility to help you feel better. I have little doubt that when we have the most efficacious therapies against the disease, people are going to feel better. So don’t view it as some sort of impossible thing to achieve. It’s a complex endpoint. It may not necessarily be a primary endpoint for a trial, but that doesn’t mean that it doesn’t matter, because in most of the studies that we’ve done, it’s been very clear that that is the number one thing that people complain about.
Now, there are other things that are more subtle, but we can’t really lose sight of them either. We’re clearly trying to prevent thrombosis and bleeding. There are symptoms that can be very devastating. Pruritus can be very, very difficult for folks. Spleen can be an issue. Anemia can be an issue. But what is other benefit? Well, living your life as normally as possible. I share with patients, again, our goal is to try to have the disease be as invisible in your life as possible. That can be doing the activities that you wish. That can be around employment. That can be around spending less of your life really consumed with aspects of your medical care. And it clearly can include issues of financial toxicity.
What about living longer? And again, we’ve already had a great discussion today, and I think it’s a good one. How do we actually build the evidentiary case of what really links to better overall survival? Again, having perspective on these diseases, in myelofibrosis I do think our patients are living longer. There is no question. As a group, I don’t think that necessarily extends to every individual, but as a group, there is just no question. You know, at the beginning of my career, you could go through the waiting room and you could pick out who had myelofibrosis in the room before you even saw them back in clinic. They were cachectic. They had a gray color. You could see the muscle wasting. You could see the tremendous imbalance of splenomegaly that these people had. So it was very much a burden. And people are living longer now. Still, we clearly still have individuals that we lose.
Now, we still don’t fully understand why people live longer, but it’s much more than some sort of superficial “they’re just having fewer symptoms.” I think the improvement in symptoms is a biomarker in terms of the efficacy of the therapies that we have seen. I do think that we are poised to better understand some of the information that we already have. So this AI revolution, I think, in part will be helpful. And as I think about AI, one of the ways it’s helpful is I think it better allows us to understand all of the data that we have really accumulated in the past. And I think one thing that we have kind of jettisoned as a field is really histology, in part because histology has not helped us, at least in this era of therapy development. But I hope that we’re able to move past that and gather more information that may help us beyond just the mutant allele burden.
Now, what about symptoms as an endpoint? What have we learned? So first, we really started this because individuals like Werner, patients, really pushed us forward, saying, “Boy, symptoms matter. The doctors are largely ignoring us. How do we help demonstrate that this matters? How do we help measure them?” And Joyce Niblack, who subsequently passed from the disease, really was a voice behind this, and the MPN Research Foundation had been a strong supporter of this very early on, as a very patient-centered organization, asking how do we really figure this out? And again, we can only figure it out really in the context of clinical trials. So the clinical trials have really had a symbiotic relationship with this development, because the only way you validate a change is you’ve got to be doing something that hopefully makes a difference, so you can really see that delta.
Now, let’s just talk a moment about fatigue, because fatigue has been kind of the rock that several trials have really tripped over on their path. And this is an AI-generated image, but not by myself, by patients. So this was from one of the patient Facebook groups, trying to really convey the issue that fatigue in MPNs is different. This is not just the typical tiredness of, “Oh my gosh, I’ve been in clinic all day,” or “I’ve been in this long conference,” or “I’ve been at the airport.” This is a pathologic state. It’s a bit like when you have the flu and you wake up in the morning, and you’ve allegedly slept all night, and you still feel like you just got hit by a bus, and it’s eight in the morning. It feels wrong. And again, this is one of the major challenges that they face. So patients are trying to really be a support for each other in terms of giving each other tips, as well as reassurance that what you’re feeling is not in isolation. We hear you; we see the difficulty that you have in trying to overcome this fatigue.
Now, it is very true that fatigue as a symptom, very interestingly, of all the individual symptoms, is the highest in the general public. So this was a very nice study by Dr. Anderson in the UK, where they had age-matched normal population controls, comparing the general population to MPN patients, and this was just compared to ET and PV patients. They found that there’s a clear statistical difference for every symptom between MPN patients and the general public. And that fatigue, yes, is higher in the general public, but it is that much higher in patients with MPNs.
So what have we learned about MPN symptoms as trial endpoints? So first, we have learned that they are both measurable and reproducible. And indeed, the symptom data are probably the most consistently performing data across clinical trials of anything we really have had. Fatigue as a symptom is higher at the natural baseline, but that still doesn’t mean that we can’t measure or see the difference. We’ve already discussed that TSS is just one lens for assessing response, and I do think that there is additional opportunity for investigating other ways of looking at the response of symptoms, even with the same methodology that has been fairly consistent. And then that 50% reduction, I think it can be a very coarse way to look at these things.
So what does this mean in terms of the specific trials we’ve had as they relate to myelofibrosis? So first, we see that it clearly can perform in an adequate way to really represent this benefit, and it has been involved with the approval of several agents, including momelotinib as an example. But again, it has validity, meaning it’s measurable, it changes, but it also really matches our clinical experience when we visit with patients.
Now, we know as well that in the frontline setting, it can be challenging. And the SENTRY study is a prime example of a study where the therapy showed a whole variety of different benefits, and may well even show a survival benefit. But in terms of symptom benefit, beating ruxolitinib in the frontline setting is challenging. There’s X amount of improvement in the baseline level of symptoms. And is it really feasible to see a statistically significant difference in 24 weeks between a combination versus a single agent? It may well be a very challenging bar to overcome. One, 24 weeks is a short amount of time. It worked really well for JAK inhibitors versus a placebo. It really may not be a feasible time frame or construct to really have that expectation.
Now, measuring changes in symptoms and fatigue still remains very possible. Sometimes it’s easier to demonstrate in the second-line setting. So this is with nuvisertib. Again, showing that despite fatigue having a higher level at baseline, there’s a clear benefit that really can be seen for these individuals. Similarly with the updated JAK inhibitor story from Ajax, which John presented at EHA. Again, in the second-line setting, a very significant reduction in symptoms was still able to be observed, including fatigue. So I don’t think that it is an impossible thing to improve, but in the frontline setting it really might be challenging.
So I’ll conclude by saying, as we think about symptoms, frontline and second-line, particularly in comparison to single-agent JAK inhibitors, it is tricky. That’s one of the things JAK inhibitors do the best, and it doesn’t mean that a combination is not better in the frontline setting, but beating symptoms in this setting may be a fool’s errand. Proving superiority is challenging. There may be additional metrics of quality of life which may be very relevant in terms of the overall cumulative benefit. In the second-line setting, I think it may be a bit of a clearer story, because then you’re already dealing with a situation where that need has really not been met. And without question, I strongly believe, with everything that’s been discussed here, we need to validate other surrogate endpoints. But I think, as we’ve heard, it’s going to take aggregate data, and it’s going to take probably a different methodology than we have pursued to really be able to achieve this in a meaningful way.
So, again, thanks for all the work on symptoms. It really has been a highly collaborative effort. Alas, we have no such fun hats here, Charlie, for the Washington one; a challenge for the next iwMPN meeting. So next, let me invite up John Mascarenhas for the next discussion as part of this session. Thank you.
AI-generated transcript. Please refer to the video as the authoritative source.
Read more...
